Approval · Notice of Compliance 36396 · 2025
ACH-GABAPENTIN: Notice of Compliance 36396
Issued November 18, 2025
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 36396
- Date
- November 18, 2025
- Company
- Accord Healthcare IncKirkland, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- Administrative: Change in product name. Update to Product Monograph (to align with CRP approved PM)
- Canadian reference product
- NEURONTIN (Pfizer Canada Ulc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ACH-GABAPENTIN | 02416840 | Marketed |
| ACH-GABAPENTIN | 02416859 | Marketed |
| ACH-GABAPENTIN | 02416867 | Marketed |
| ACH-GABAPENTIN | 02392526 | Marketed |
| ACH-GABAPENTIN | 02392534 | Dormant |
Medicinal ingredients
- GABAPENTIN 100 MG per CAP
- GABAPENTIN 300 MG per CAP
- GABAPENTIN 400 MG per CAP
- GABAPENTIN 600 MG per TAB
- GABAPENTIN 800 MG per TAB